PURPOSE: The metastatic tumor antigen (MTA) gene is a recently identified metastasis-associated gene which has implications in the signal transduction or regulation of gene expression. However, the expression of MTA in osteosarcoma and its potential relationship with metastasis have not been examined, forming the basis of this study. MATERIALS AND METHODS: We compared the expression levels of the MTA1 protein between 32 cases of high-grade osteosarcomas and 21 cases of low-grade osteosarcomas by immunohistochemistry. In addition, the mRNA expression levels of MTA1, 2, 3 in these osteosarcoma cell lines and control fibroblasts were evaluated by real-time quantitative PCR. RESULTS: MTA1 immunoreactivity was present in 81.25% of high-grade osteosarcoma specimens. Its expression was predominantly localized to the nucleus or cytoplasm of osteosarcoma cells. Thirteen (86.6%) of 15 patients who died of osteosarcomas displayed strong MTA1 expression. Both primary bone and pulmonary metastatic lesions exhibited MTA1 expression. All low-grade osteosarcomas were negative for MTA1 except for focal weak reactivity in two cases. The tested high-grade osteosarcoma cell lines showed marked amplification of MTA1 and MTA2 mRNA compared to control cells. CONCLUSION: These results suggest that MTA might be involved in the progression of high-grade osteosarcoma, particularly in hematogenous metastasis of osteosarcoma.
PURPOSE: The metastatic tumor antigen (MTA) gene is a recently identified metastasis-associated gene which has implications in the signal transduction or regulation of gene expression. However, the expression of MTA in osteosarcoma and its potential relationship with metastasis have not been examined, forming the basis of this study. MATERIALS AND METHODS: We compared the expression levels of the MTA1 protein between 32 cases of high-grade osteosarcomas and 21 cases of low-grade osteosarcomas by immunohistochemistry. In addition, the mRNA expression levels of MTA1, 2, 3 in these osteosarcoma cell lines and control fibroblasts were evaluated by real-time quantitative PCR. RESULTS:MTA1 immunoreactivity was present in 81.25% of high-grade osteosarcoma specimens. Its expression was predominantly localized to the nucleus or cytoplasm of osteosarcoma cells. Thirteen (86.6%) of 15 patients who died of osteosarcomas displayed strong MTA1 expression. Both primary bone and pulmonary metastatic lesions exhibited MTA1 expression. All low-grade osteosarcomas were negative for MTA1 except for focal weak reactivity in two cases. The tested high-grade osteosarcoma cell lines showed marked amplification of MTA1 and MTA2 mRNA compared to control cells. CONCLUSION: These results suggest that MTA might be involved in the progression of high-grade osteosarcoma, particularly in hematogenous metastasis of osteosarcoma.
Authors: Y Toh; S Kuninaka; K Endo; T Oshiro; Y Ikeda; H Nakashima; H Baba; S Kohnoe; T Okamura; G L Nicolson; K Sugimachi Journal: J Exp Clin Cancer Res Date: 2000-03
Authors: H Sasaki; H Yukiue; Y Kobayashi; Y Nakashima; M Kaji; I Fukai; M Kiriyama; Y Yamakawa; Y Fujii Journal: Cancer Lett Date: 2001-12-28 Impact factor: 8.679
Authors: Matthias D Hofer; Rainer Kuefer; Sooryanarayana Varambally; Haojie Li; Jing Ma; Geoffrey I Shapiro; Juergen E Gschwend; Richard E Hautmann; Martin G Sanda; Klaudia Giehl; Andre Menke; Arul M Chinnaiyan; Mark A Rubin Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Brittany L Siontis; Jonathan B McHugh; Emily Roberts; Lily Zhao; Dafydd G Thomas; Dawn Owen; Laurence H Baker; J Sybil Biermann; Scott M Schuetze; Rashmi Chugh Journal: Front Oncol Date: 2020-01-22 Impact factor: 6.244